Suramin sodium salt
Based on 22 publication(s) in Google Scholar
Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor. Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM). Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM). Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor. Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.98%
- CAS No.: 129-46-4
- 화학식: C51H34N6Na6O23S6
- 분자량:1429.17
-
보관:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Metabolism/Protease Compound Library
HY-L012
-
FDA-Approved Drug Library
HY-L022
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Covalent Screening Library
HY-L036
-
Antioxidant Compound Library
HY-L037
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Glutamine Metabolism Compound Library
HY-L064
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Lung Cancer Compound Library
HY-L075
-
Phosphatase Inhibitor Library
HY-L081
-
Antiparasitic Compound library
HY-L082
-
Targeted Diversity Library
HY-L099
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Off-patent Drug Library
HY-L141
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
Epigenetics Compound Library Mini
HY-L005M
-
Covalent Screening Library Plus
HY-L036P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
RNA Binding Bioactive Compound Library
HY-L248
Publications Citing Use of MedChemExpress (MCE) Suramin sodium salt
More- J Hematol Oncol. 2025 Apr 1;18(1):38. [Abstract]
- Cell Metab. 2024 Sep 5:S1550-4131(24)00334-6. [Abstract]
- Nat Commun. 2024 Aug 27;15(1):7369. [Abstract]
- Adv Sci (Weinh). 2025 Nov 6:e14842. [Abstract]
- Nat Struct Mol Biol. 2021 Mar;28(3):319-325. [Abstract]
- Br J Pharmacol. 2021 Dec;178(23):4646-4662. [Abstract]
- J Med Chem. 2024 Aug 8;67(15):12760-12783. [Abstract]
- Clin Transl Med. 2021 Jun;11(6):e485. [Abstract]
- J Agric Food Chem. 2023 Oct 4;71(39):14263-14275. [Abstract]
- Int Immunopharmacol. 2025 Sep 6:165:115494. [Abstract]
- Int Immunopharmacol. 2023 Jul:120:110295. [Abstract]
- Phys Rev Appl. 2025 Jun 06.
- ACS Omega. 2025 Dec 8;10(50):62145-62156. [Abstract]
- Lipids Health Dis. 2023 Dec 13;22(1):222. [Abstract]
- J Biol Chem. 2021 Oct;297(4):101166. [Abstract]
- J Biol Chem. 2020 Jul 24;295(30):10281-10292. [Abstract]
- Pharmacol Biochem Behav. 2025 Dec:257:174114. [Abstract]
- Biomicrofluidics. 2019 Nov 21;13(6):064117. [Abstract]
- Behav Brain Res. 2023 Aug 24:452:114548. [Abstract]
- J Bone Miner Metab. 2023 Sep;41(5):606-620. [Abstract]
- J Virol Methods. 2021 Dec:298:114283. [Abstract]
- Research Square Preprint. 2020 Nov.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
RT-PCR
All Topoisomerase Isoforms
MoreAll Parasite Isoforms
More
Biological Activity
|
SIRT1 297 nM (IC50) |
SIRT2 1.15 μM (IC50) |
SIRT5 22 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| J774 | IC50 |
>1000 μM
Compound: S2
|
Cytotoxicity against J774.1 cell line after 48 hrs
Cytotoxicity against J774.1 cell line after 48 hrs
|
[PMID: 16516467] |
| MT4 | CC50 |
250 μM
Compound: Suramin (hexasodium salt)
|
Cytotoxicity against HIV-1 (HTLV-IIIB) in MT-4 cells
Cytotoxicity against HIV-1 (HTLV-IIIB) in MT-4 cells
|
[PMID: 8336338] |
| MT4 | EC50 |
8.2 μM
Compound: Suramin (hexasodium salt)
|
Antiviral activity against HIV-1 (HTLV-IIIB) in MT-4 cells
Antiviral activity against HIV-1 (HTLV-IIIB) in MT-4 cells
|
[PMID: 8336338] |
Suramin sodium salt (Suramin hexasodium salt; 50-600 μg/mL; for 24-96 hours) inhibits cells proliferation in a dose-dependent and time-dependent manner and decreases viability in cancer cells[7].
Suramin sodium salt (300 μg/mL; for 48 hours) induces cells apoptosis and down-regulates mRNA expression in HeLa cells[7].
Suramin sodium salt (1 mg/mL; 1 hour) significantly suppresses the phosphorylated ERK1/2[8].
The IC50 values of HO-8910 PM and HeLa are 319 μg/mL, 476 μg/mL, respectively[7].
Suramin blocks viral replication in Vero E6 cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HO-8910 PM ovarian and Hela cervical cancer cells
-
Concentration:50, 100, 200, 300, 400, 500 and 600 μg/mL
-
Incubation Time:For 24, 48, 72 and 96 hours
-
Result:Inhibited cells proliferation in a dose-dependent and time-dependent manner.
-
Cell Line:HeLa cells
-
Concentration:300 μg/mL
-
Incubation Time:For 48 hours
-
Result:Induced cells apoptosis.
-
Cell Line:PA-SMCs cells
-
Concentration:1 mg/mL
-
Incubation Time:For 1 hour
-
Result:Significantly suppressed the phosphorylated ERK1/2.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male Wistar rats (200-225 g)[7]
-
Dosage:10 mg/kg
-
Administration:IV; twice weekly for 3 weeks
-
Result:Reversed established PH, thereby normalizing the pulmonary artery pressure values and vessel structure.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 129-46-4
-
Appearance Solid
-
분자량 1429.17
-
화학식 C51H34N6Na6O23S6
-
Color Off-white to light brown
-
SMILES
O=C(NC1=CC(C(NC2=CC(C(NC3=CC=C(S(=O)(O[Na])=O)C4=CC(S(=O)(O[Na])=O)=CC(S(=O)(O[Na])=O)=C34)=O)=CC=C2C)=O)=CC=C1)NC5=CC(C(NC6=CC(C(NC7=CC=C(S(=O)(O[Na])=O)C8=CC(S(=O)(O[Na])=O)=CC(S(=O)(O[Na])=O)=C78)=O)=CC=C6C)=O)=CC=C5
-
Synonyms
Suramin hexasodium salt
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (22)
-
Journal Impact Factor
-
Most Recent
-
J Hematol Oncol
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function. [Abstract]2025 Apr 1;18(1):38. PMID: 40170099 -
Cell Metab
Dietary-timing-induced gut microbiota diurnal oscillations modulate inflammatory rhythms in rheumatoid arthritis. [Abstract]2024 Sep 5:S1550-4131(24)00334-6. PMID: 39260371 -
Nat Commun
2024 Aug 27;15(1):7369. PMID: 39191796 -
Adv Sci (Weinh)
2025 Nov 6:e14842. PMID: 41195564 -
Nat Struct Mol Biol
2021 Mar;28(3):319-325. PMID: 33674802 -
Br J Pharmacol
Transient Receptor Potential channels, TRPV1 and TRPA1 in melanocytes synergize UV-dependent and UV-independent melanogenesis. [Abstract]2021 Dec;178(23):4646-4662. PMID: 34363226 -
J Med Chem
Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CLpro Inhibitors as anti-SARS-CoV-2 Drug Candidate. [Abstract]2024 Aug 8;67(15):12760-12783. PMID: 39072488 -
Clin Transl Med
Aberrant MCM10 SUMOylation induces genomic instability mediated by a genetic variant associated with survival of esophageal squamous cell carcinoma. [Abstract]2021 Jun;11(6):e485. PMID: 34185429 -
J Agric Food Chem
Ginsenoside F4 Alleviates Skeletal Muscle Insulin Resistance by Regulating PTP1B in Type II Diabetes Mellitus. [Abstract]2023 Oct 4;71(39):14263-14275. PMID: 37726223 -
Int Immunopharmacol
The immunoregulator β-glucan produces antidepressant effects through microglia-mobilized astrocytic P2Y1R-BDNF signaling in the dentate gyrus. [Abstract]2025 Sep 6:165:115494. PMID: 40915186 -
Int Immunopharmacol
Suramin ameliorates osteoarthritis by acting on the Nrf2/HO-1 and NF-κB signaling pathways in chondrocytes and promoting M2 polarization in macrophages. [Abstract]2023 Jul:120:110295. PMID: 37182454 -
-
ACS Omega
2025 Dec 8;10(50):62145-62156. PMID: 41476561
Suramin sodium salt purchased from MedChemExpress. Usage Cited in: ACS Omega. 2025 Dec 8;10(50):62145-62156. [Abstract]
Suramin sodium salt (0-100 μM, 24 h) showed a dose-dependent inhibition in Vero cells when they were infected with 1 MOI of GFP-wtCHIKV.
-
Lipids Health Dis
Suramin, an antiparasitic drug, stimulates adipocyte differentiation and promotes adipogenesis. [Abstract]2023 Dec 13;22(1):222. PMID: 38093311
Suramin sodium salt purchased from MedChemExpress. Usage Cited in: Lipids Health Dis. 2023 Dec 13;22(1):222. [Abstract]
Suramin sodium salt (35, 70, 105, and 140 µM, 2-4 days) showed no cytotoxicity at 35 and 70 µM, but exhibited a cytotoxic effect by decreasing cell viability at 105 and 140 µM in fascial preadipocytes.
Suramin sodium salt purchased from MedChemExpress. Usage Cited in: Lipids Health Dis. 2023 Dec 13;22(1):222. [Abstract]
Suramin sodium salt (35–140 µM, 5 days) elevated LDH release at 105 and 140 µM in fascial preadipocytes.
Suramin sodium salt purchased from MedChemExpress. Usage Cited in: Lipids Health Dis. 2023 Dec 13;22(1):222. [Abstract]
Suramin (70 µM, 9 days) induced adipogenic differentiation of fascial stromal preadipocytes.
Suramin sodium salt purchased from MedChemExpress. Usage Cited in: Lipids Health Dis. 2023 Dec 13;22(1):222. [Abstract]
Suramin (0–70 µM, 5 days) increased the expression of adipogenic genes (left) and mature adipocyte marker gene (right) on day 5.
-
J Biol Chem
Type 2 diabetic mice enter a state of spontaneous hibernation-like suspended animation following accumulation of uric acid. [Abstract]2021 Oct;297(4):101166. PMID: 34487763 -
J Biol Chem
Suramin and NF449 are IP5K inhibitors that disrupt inositol hexakisphosphate-mediated regulation of cullin-RING ligase and sensitize cancer cells to MLN4924/pevonedistat. [Abstract]2020 Jul 24;295(30):10281-10292. PMID: 32493769
Suramin sodium salt purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2020 Jul 24;295(30):10281-10292. [Abstract]
Suramin inhibits IP5K function in vivo. Immunoprecipitation of myc-CSN2 from myc-CSN2-HEK293 stable cell after IP5K knockdown, with or without Suramin or NF449 treatment.
-
Pharmacol Biochem Behav
Intranasal LAG3 antibody infusion induces microglia-dependent antidepressant effect by mobilizing astrocytic P2Y1R-mediated BDNF synthesis in the hippocampus. [Abstract]2025 Dec:257:174114. PMID: 41106438 -
Biomicrofluidics
Calcium response in bone cells at different osteogenic stages under unidirectional or oscillatory flow. [Abstract]2019 Nov 21;13(6):064117. PMID: 31768203 -
Behav Brain Res
Electroacupuncture-Modulated Extracellular ATP Levels in Prefrontal Cortex Ameliorated Depressive-like Behavior of Maternal Separation Rats. [Abstract]2023 Aug 24:452:114548. PMID: 37355234 -
J Bone Miner Metab
Extracellular ATP-induced calcium oscillations regulating the differentiation of osteoblasts through aerobic oxidation metabolism pathways. [Abstract]2023 Sep;41(5):606-620. PMID: 37418073 -
J Virol Methods
Surface plasmon resonance approach to study drug interactions with SARS-CoV-2 RNA-dependent RNA polymerase highlights treatment potential of suramin. [Abstract]2021 Dec:298:114283. PMID: 34534610 -
용액&용해도
DMSO : 50 mg/mL (34.99 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (34.99 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (1.46 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (1.46 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (69.97 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
순도&문서
-
Data Sheet (280 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhang YL, et al. Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases. J Biol Chem. 1998 May 15;273(20):12281-7. [Content Brief]
[2]. Trapp J, et al. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). ChemMedChem. 2007 Oct;2(10):1419-31. [Content Brief]
[3]. Schuetz A, et al. Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin. Structure. 2007 Mar;15(3):377-89. [Content Brief]
[4]. De Clercq E, et al. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett. 1979 Nov;8(1):9-22. [Content Brief]
[5]. Wanchao Yin, et al. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nat Struct Mol Biol. 2021 Mar;28(3):319-325. [Content Brief]
[6]. Jindal HK, et al. Suramin affects DNA synthesis in HeLa cells by inhibition of DNA polymerases. Cancer Res. 1990 Dec 15;50(24):7754-7. [Content Brief]
[7]. Xiaozhe Zhang, et al. Suramin and NF449 Are IP5K Inhibitors That Disrupt IP6-mediated Regulation of Cullin RING Ligase and Sensitize Cancer Cells to MLN4924/pevonedistat. J Biol Chem. 2020 Jun 3;jbc.RA120.014375. [Content Brief]
[8]. Novaes RD, et al. Purinergic Antagonist Suramin Aggravates Myocarditis and Increases Mortality by EnhancingParasitism, Inflammation, and Reactive Tissue Damage in Trypanosoma cruzi-Infected Mice. Oxid Med Cell Longev. 2018 Sep 30;2018:7385639. [Content Brief]
[9]. Izikki M, et al. The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats. PLoS One. 2013 Oct 15;8(10):e77073. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 0.6997 mL | 3.4985 mL | 6.9971 mL | 17.4927 mL |
| 5 mM | 0.1399 mL | 0.6997 mL | 1.3994 mL | 3.4985 mL | |
| 10 mM | 0.0700 mL | 0.3499 mL | 0.6997 mL | 1.7493 mL | |
| 15 mM | 0.0466 mL | 0.2332 mL | 0.4665 mL | 1.1662 mL | |
| 20 mM | 0.0350 mL | 0.1749 mL | 0.3499 mL | 0.8746 mL | |
| 25 mM | 0.0280 mL | 0.1399 mL | 0.2799 mL | 0.6997 mL | |
| 30 mM | 0.0233 mL | 0.1166 mL | 0.2332 mL | 0.5831 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz